There are currently 172 active clinical trials seeking participants for Heart Failure research studies. The states with the highest number of trials for Heart Failure participants are California, Florida, Texas and New York.
The Impact of an Adaptive Patient-centered Web Application on Medication Optimization in HFrEF Patients
Recruiting
The SmartHF study is a 12-week prospective randomized controlled multicenter clinical trial. This study will investigate the efficacy of an adaptive web application to facilitate guideline-directed medical therapy (GDMT) optimization in HFrEF patients. Eligible participants will be randomized to the web application intervention or control in a 1:1 manner, stratified by site. The intervention is an adaptive medication optimization web application that extracts and analyzes the EHR data with a co... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Emory University, Grady Hospital, Atlanta, Georgia +4 locations
Conditions: Heart Failure
Assessment of CCM in HF With Higher Ejection Fraction
Recruiting
The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤70%.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Grandview Medical Group Research, LLC, Birmingham, Alabama +103 locations
Conditions: Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Heart Failure With Moderately Reduced Ejection Fraction, Diastolic Heart Failure
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
Recruiting
This randomized pilot phase I trial studies the side effects of donor bone marrow derived mesenchymal stem cells in controlling heart failure in patients with cardiomyopathy caused by anthracyclines. Donor bone marrow derived mesenchymal stem cells may help to control symptoms of heart failure and improve heart function.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/01/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Cardiomyopathy, Heart Failure, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Heart Failure Precision Medicine Study
Recruiting
The study aims to test the hypothesis that multi-omics studies can identify Heart Failure profiles at risk of adverse outcomes and evaluate a telemonitoring intervention in the optimization of guideline-directed medical therapy.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
05/31/2025
Locations: UC Davis Medical Center, Sacramento, California
Conditions: Heart Failure
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
Recruiting
The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.
Gender:
ALL
Ages:
All
Trial Updated:
05/30/2025
Locations: Not set, Birmingham, Alabama +311 locations
Conditions: Arrhythmia, Bradycardia, Heart Failure, Sinus Tachycardia
Staged Kidney Transplantation During Combined Heart/Kidney Transplantation
Recruiting
The primary purpose of this study is to evaluate the safety and efficacy of ex vivo machine perfusion with staged implantation of kidney allografts during combined heart/kidney transplantation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2025
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Heart Failure, Chronic Kidney Disease, End-stage Kidney Disease
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
Recruiting
Participants include men and women ≥ 40 years of age with T2DM, established CV disease, a history of HTN with an SBP of at least 130 mmHg at screening, who meet the predefined serum potassium level, and with at least one additional risk factor for HF. The study will include an optional pre-screening period to facilitate sites' identification of potentially eligible participants to enter the full screening assessments. Participants will not be required to visit the site and no informed consent i... Read More
Gender:
ALL
Ages:
40 years and above
Trial Updated:
05/29/2025
Locations: Research Site, Birmingham, Alabama +806 locations
Conditions: Heart Failure
Early Feasibility Study of the NORM™ System in Heart Failure Patients (FUTURE-HFII)
Recruiting
Early Feasibility Study of the NORM™ System in Heart Failure Patients
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: Columbia University Irving Medical Center/ New York Presbyterian Hospital, New York, New York +5 locations
Conditions: Heart Failure
Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
Recruiting
Powerful new drugs that can prevent or delay end stage kidney disease (ESKD) - so called sodium-glucose cotransporter-2 inhibitors (SGLT2i) - are now available for patients with type 2 diabetes. Whether these drugs have similar effects in patients with type 1 diabetes (T1D) remains unknown because of the few studies in this population, due to concerns about the increase in risk of diabetic ketoacidosis (DKA, a serious, potentially fatal acute complication of diabetes due to the accumulation of s... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/28/2025
Locations: Stanford University Medical Center, Stanford, California +17 locations
Conditions: Diabetic Nephropathies, Kidney Failure, Chronic, Diabetes Mellitus Type 1, Heart Failure
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
Recruiting
The purpose of this study is to evaluate the safety, tolerability, and exposure-response (E-R) of BMS-986435/MYK-224 in participants with symptomatic Heart Failure with Preserved Ejection Fraction (HFpEF).
Gender:
ALL
Ages:
Between 40 years and 90 years
Trial Updated:
05/27/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +114 locations
Conditions: Heart Failure
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
Recruiting
This will be a global Phase IV, open-label, randomised study to evaluate the safety and tolerability of acalabrutinib (monotherapy, 100 mg orally \[po\], twice daily \[bd\]) compared to investigator's choice of treatment, in patients with CLL (TN or R/R) and moderate to severe cardiac impairment. All patients will have cardiac impairment as defined by LVEF of \< 50%. Randomisation will be stratified by LVEF \> 40% vs ≤ 40% to stratify for moderate and severe cardiac impairment, which for this s... Read More
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
05/26/2025
Locations: Research Site, Charlotte, North Carolina +22 locations
Conditions: Chronic Lymphocytic Leukaemia, Heart Failure
A Multi-center, National, Open-label, Prospective Study to Evaluate the Performance of the V-Lap™ System
Recruiting
The objective of this study is to evaluate the safety and performance of the V-LAP System in subjects with New York Heart Association (NYHA) functional class II and III HF, irrespective of left ventricular ejection fraction.
Gender:
ALL
Ages:
Between 22 years and 88 years
Trial Updated:
05/25/2025
Locations: One Boston Medical Center Place, Boston, Massachusetts
Conditions: Heart Failure